OSI Pharmaceuticals announces management changes to eye diseasebusiness team

Pharmaceuticals Inc. announced management changes to its OSI/Eyetech Pharmaceuticals business team. Paul G. Chaney, chief operating officer of OSI/Eyetech, has been promoted to the role of executive vice president, OSI Pharmaceuticals, and president of OSI/Eyetech.

In his new role, Chaney will report to Colin Goddard, PhD, chief executive officer of OSI Pharmaceuticals. Chaney will assume operational leadership of the company's eye disease franchise that includes its neovascular age-related macular degeneration product, pegaptanib sodium injection (Macugen).

The company also announced that David R. Guyer, MD, executive vice president, OSI Pharmaceuticals, and chief executive officer, OSI/Eyetech, is leaving to accept a position as venture partner at SV Life Sciences (formerly Schroders). Dr. Guyer will continue to play a role with OSI Pharmaceuticals as a consultant providing input in ophthalmology and retinal disease to its management team and board for the eye disease area.

For more information, visit OSI/Eyetech Pharmaceuticals at Booths 401, 403, and 405.